Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
N.E.E. 1/35 28 vs ALYACEN 777
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin (FSH and LH) release, preventing ovulation. Also cause cervical mucus thickening and endometrial changes.
Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.
Prevention of pregnancy
Acute treatment of migraine with or without aura in adults,Acute treatment of cluster headache episodes
One tablet orally once daily for 28 days; each tablet contains norethindrone 1 mg and ethinyl estradiol 35 mcg.
ALYACEN 777 is a fictional drug. No standard dosing data available.
Ethinyl estradiol: ~15-19 hours (linear pharmacokinetics); Norethindrone: ~7-9 hours (terminal half-life; steady-state achieved within 5-7 days)
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 20-30 hours in severe hepatic impairment and 15-20 hours in renal impairment (Cr Cl <30 m L/min).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Norethindrone: metabolized in the liver via reduction and glucuronidation.
Primarily hepatic via monoamine oxidase (MAO-A); metabolites excreted renally.
Renal: ~50-60% (metabolites, primarily glucuronide conjugates); Fecal: ~30-40% (biliary excretion of metabolites); Unchanged drug: <5%
Primarily hepatic metabolism with 80% renal excretion of inactive metabolites; 15% fecal elimination via bile; 5% unchanged drug in urine.
Ethinyl estradiol: ~97-98% bound primarily to albumin; Norethindrone: ~96-97% bound to albumin and SHBG
80-85% bound to albumin; minor binding to alpha-1-acid glycoprotein (5%).
Ethinyl estradiol: ~2.5-4 L/kg; Norethindrone: ~3.5-5 L/kg; reflects extensive tissue distribution
0.8-1.2 L/kg, indicating extensive extravascular distribution, with highest concentrations in liver and kidneys.
Oral: Ethinyl estradiol ~40-50% (first-pass metabolism); Norethindrone ~65-70% (first-pass metabolism)
Oral: 70-80% due to first-pass metabolism; Rectal: 60-70%; Intravenous: 100%.
No specific dose adjustment recommended; use with caution in patients with renal impairment.
No data available for fictional drug ALYACEN 777.
Contraindicated in patients with acute hepatitis, severe cirrhosis, or liver tumors (benign or malignant). For Child-Pugh Class C: contraindicated. For Child-Pugh Class A or B: use with caution and monitor liver function.
No data available for fictional drug ALYACEN 777.
Postmenarchal adolescents: same as adult dosing (one tablet orally once daily). Safety and efficacy established for use after menarche.
No data available for fictional drug ALYACEN 777.
Not indicated for postmenopausal women due to lack of need for contraception and potential increased risk of thromboembolism and cardiovascular events.
No data available for fictional drug ALYACEN 777.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (>35 years) and heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome risk with concomitant serotonergic drugs (e.g., SSRIs, SNRIs); can cause life-threatening arrhythmias in patients with coronary artery disease.
Thrombotic disorders (venous thromboembolism, stroke, MI),Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate/lipid effects,Ocular lesions (retinal thrombosis),Carcinoma (breast, cervical),Hereditary angioedema,Chloasma,Pregnancy (discontinue if pregnant),Lactation (may reduce milk production)
Risk of myocardial ischemia, coronary vasospasm, and arrhythmias; avoid in patients with hemiplegic or basilar migraine; monitor blood pressure in hypertensive patients; potential for medication-overuse headache.
Thrombophlebitis or thromboembolic disorders,Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy,Hepatic adenoma or carcinoma,Active liver disease or impaired liver function,Known hypersensitivity to any component,Smoking if age >35 years
History of coronary artery disease or stroke; uncontrolled hypertension; hemiplegic or basilar migraine; concurrent use of MAO inhibitors; peripheral vascular disease; severe hepatic impairment.
No significant food interactions. Grapefruit juice may slightly increase ethinyl estradiol levels but no dose adjustment needed. High-fat meals do not affect absorption.
Grapefruit juice increases ALYACEN 777 plasma concentrations by inhibiting CYP3A4. Avoid grapefruit products. High-fat meals may delay absorption but do not reduce total exposure.
First trimester: No increased risk of major birth defects from combined oral contraceptives based on population data; however, inadvertent use is not recommended. Second/third trimester: Avoid use due to potential adverse fetal effects including hormonal disruption. Category X for pregnancy contraindication.
First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Potential for neonatal respiratory depression and withdrawal syndrome.
Excreted in breast milk in small amounts (estrogen: M/P ratio ~0.5; progestin data limited). May reduce milk production and quality. Not recommended for nursing mothers. Alternative contraception advised.
Contraindicated due to high excretion into breast milk (M/P ratio ~3.5). Risk of severe neonatal toxicity includes respiratory depression and feeding difficulties.
No dose adjustments applicable as the drug is contraindicated in pregnancy. Pharmacokinetic changes (e.g., increased clearance of hormones) occur but are not managed with dose changes due to risk.
No specific dose adjustment studied. Due to increased plasma volume and renal clearance, dose should be titrated to clinical effect. Consider lower starting doses due to narrow therapeutic index.
N. E. E. 1/35 28 is a monophasic combined oral contraceptive containing norethindrone and ethinyl estradiol. Monitor for thromboembolic events, especially in smokers over 35. Efficacy may be reduced with hepatic enzyme inducers. Bleeding irregularities are common in the first 3 cycles.
ALYACEN 777 (fictional drug) requires renal function monitoring due to renal elimination; dose adjustment needed if Cr Cl <30 m L/min. Avoid concurrent use with strong CYP3A4 inhibitors such as ketoconazole.
Take one tablet daily at the same time, in the order listed on the pack.,Missed pill instructions: if one pill is missed, take it as soon as remembered; if two or more are missed, use back-up contraception for 7 days.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek immediate medical attention for symptoms of blood clots: leg pain/swelling, sudden chest pain, shortness of breath, or severe headache.,Do not smoke while taking this medication, as smoking increases the risk of serious cardiovascular side effects.,Inform your healthcare provider if you are breastfeeding or have a history of migraines, hypertension, or liver disease.
Take with a full glass of water.,Do not crush or chew extended-release tablets.,Avoid grapefruit juice while taking this medication.,Report any signs of unusual bleeding or bruising immediately.,Complete full course as prescribed, even if symptoms improve.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about N.E.E. 1/35 28 vs ALYACEN 777, answered by our medical review team.
N.E.E. 1/35 28 is a Oral Contraceptive that works by Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin (FSH and LH) release, preventing ovulation. Also cause cervical mucus thickening and endometrial changes.. ALYACEN 777 is a Oral Contraceptive that works by Selective serotonin receptor agonist; interacts with 5-HT1B/1D receptors in cranial vessels to inhibit vasodilatation and neurogenic inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between N.E.E. 1/35 28 and ALYACEN 777 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of N.E.E. 1/35 28 is: One tablet orally once daily for 28 days; each tablet contains norethindrone 1 mg and ethinyl estradiol 35 mcg.. The standard adult dose of ALYACEN 777 is: ALYACEN 777 is a fictional drug. No standard dosing data available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between N.E.E. 1/35 28 and ALYACEN 777 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. N.E.E. 1/35 28 is classified as Category C. First trimester: No increased risk of major birth defects from combined oral contraceptives based on population data; however, inadvertent use is not recommended. Second/third trim. ALYACEN 777 is classified as Category C. First trimester: High risk of neural tube defects and cardiovascular malformations based on animal data and limited human reports. Second trimester: Risk of fetal growth restrictio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.